A review of the iStent® trabecular micro-bypass stent: safety and efficacy
Sarah R Wellik, Elizabeth A DaleDepartment of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, FL, USAAbstract: There is a significant demand for procedures that can effectively treat glaucoma with low risk and good visual outcomes. To fill this void, procedures termed &ld...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b8c0878fcaf64c8f994e1b69a8cca525 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | Sarah R Wellik, Elizabeth A DaleDepartment of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, FL, USAAbstract: There is a significant demand for procedures that can effectively treat glaucoma with low risk and good visual outcomes. To fill this void, procedures termed “minimally invasive glaucoma surgery”, are gaining in popularity. This review will focus on the safety and efficacy of one such minimally invasive glaucoma surgery procedure, the trabecular micro-bypass stent. This stent is intended to lower intraocular pressure by directly cannulating Schlemm’s canal and thereby enhancing aqueous outflow. Recent randomized controlled trials and case series have demonstrated the micro-bypass stent to be a relatively safe procedure, with limited complications and no serious adverse sequelae. The most common complication across all studies was stent obstruction or malposition, which generally did not result in any adverse outcome in vision or pressure control. In addition, increased rates of hypotony, choroidal hemorrhage, or infection were not seen with the micro-bypass stent in comparison to cataract surgery alone.Keywords: glaucoma, minimally invasive glaucoma surgery, MIGS, Schlemm’s canal |
---|